<DOC>
	<DOCNO>NCT03008369</DOCNO>
	<brief_summary>This phase II trial study well lenvatinib work treat patient pheochromocytoma paraganglioma spread place body remove surgery . Lenvatinib may stop growth tumor cell block enzymes need cell growth .</brief_summary>
	<brief_title>Lenvatinib Treating Patients With Metastatic Advanced Pheochromocytoma Paraganglioma That Can Be Removed Surgery</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine anti-tumor activity lenvatinib ( overall response rate ; [ ORR ] ) patient metastatic advance unresectable pheochromocytoma paragangliomas . SECONDARY OBJECTIVES : I . To determine progression-free survival ( PFS ) . II . To determine overall survival ( OS ) . III . To determine duration tumor response . IV . To determine safety tolerability lenvatinib . V. To assess patient report quality life use EuroQol Five-Dimensional Five Level Scale Questionnaire ( EQ-5D-5L ) Functional Assessment Cancer Therapy-General ( FACT-G ) . TERTIARY OBJECTIVES : I . For patient secretory tumor , examine change plasma metanephrine level urinary catecholamine and/or metanephrine level . II . For patient secretory tumor , examine whether lenvatinib-induced change plasma metanephrines urinary catecholamine and/or metanephrine level first cycle treatment may associate objective tumor response . III . To examine association tumor response somatic mutational status archive tumor , germline mutational status ( presence SDHD , SDHB , RET , VHL , neurofibromatosis type-1 ) . OUTLINE : Patients receive lenvatinib orally ( PO ) daily ( QD ) day 1-28 . Courses repeat every 28 day 5 year absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 6 month 5 year .</detailed_description>
	<mesh_term>Pheochromocytoma</mesh_term>
	<mesh_term>Paraganglioma</mesh_term>
	<mesh_term>Carotid Body Tumor</mesh_term>
	<mesh_term>Lenvatinib</mesh_term>
	<criteria>Histologically cytologically confirm malignant secretory nonsecretory pheochromocytoma paraganglioma unresectable deem inappropriate alternative local regional therapeutic approach Measurable disease Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 , 1 , 2 Life expectancy &gt; 24 week Absolute neutrophil count ( ANC ) &gt; = 1500/mm^3 White blood cell ( WBC ) count &gt; = 3,000/mm^3 Platelet count &gt; = 100,000/mm^3 Hemoglobin &gt; = 9.0 g/dL ( 5.6 mmol/L ) ; NOTE : transfusion allow = &lt; 7 day prior registration Total bilirubin = &lt; 1.5 X upper limit normal ( ULN ) ( total bilirubin = &lt; 3.0 X ULN direct bilirubin = &lt; 1.5 X ULN patient welldocumented Gilbert 's Syndrome ) Aspartate transaminase ( AST/serum glutamic oxaloacetic transaminase [ SGOT ] ) = &lt; 2.5 X ULN Creatinine = &lt; 1.5 x ULN Urine protein/creatinine ratio = &lt; 1 OR 24hour urine protein &lt; 1.5 gram Negative pregnancy test do = &lt; 7 day prior registration , woman childbearing potential Blood pressure ( BP ) &lt; 150 mmHg ( systolic ) &lt; 90 mmHg ( diastolic ) ; initiation adjustment BP medication permit prior registration provide average three BP reading visit prior registration &lt; 150/90 mmHg ; NOTE : patient secretory pheochromocytoma paraganglioma REQUIRED : 1 ) evaluate consultation hypertension specialist specific experience management hypertension set catecholaminesecreting tumor ( usually endocrinologist , nephrologist , cardiologist ) , set hormoneassociated hypertension ) receive alpha betaadrenergic blockade least 714 day prior initiation lenvatinib ; hypertension specialist record patient commit closely follow patient clinical study evaluation say specialist require cycle 1 2 thereafter need basis Provide write informed consent Willing return enrol institution followup ( active monitoring phase study ) Ability complete questionnaire ( ) assistance Any follow : Pregnant woman Nursing woman Men woman childbearing potential unwilling employ adequate contraception Chemotherapy/systemic therapy , radiotherapy , immunotherapy surgery = &lt; 21 day prior registration kinase inhibitor therapy = &lt; 14 day prior registration failure recover toxicity ( grade 1 ) treatment ; NOTE : concurrent therapy octreotide allow provide tumor progression therapy demonstrate ; concurrent therapy bisphosphonates ( e.g . zoledronic acid ) denosumab also allow ; NOTE : unlimited number prior chemotherapeutic biologic therapy malignant pheochromocytoma paraganglioma permit ; include prior antiangiogenesis therapy tyrosine kinase inhibitor Active uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Receiving investigational agent Current use warfarin reason ; NOTE : patient safely transition another anticoagulant , may eligible provided criterion satisfy Any follow : Correct QT ( QTc ) prolongation ( define QTc interval &gt; = 500 msec ) Left ventricular ejection fraction ( LVEF ) &lt; institutional low limit normal ( LLN ) Frequent ventricular ectopy Evidence ongoing myocardial ischemia Receiving medication substance risk torsades de pointes ; NOTE : medication substance know risk torsades de pointes prohibit ; consult pharmacist review need Known active and/or untreated brain metastasis Known severe allergic prohibitive reaction tyrosine kinase inhibitor ( TKI ) Prior treatment lenvatinib Any follow condition : Active peptic ulcer disease Inflammatory bowel disease ( e.g. , ulcerative colitis , Crohn 's disease ) gastrointestinal condition increase risk perforation History new abdominal fistula , gastrointestinal perforation intraabdominal abscess = &lt; 84 day prior registration ; NOTE : enrollment patient chronic/canalized fistulous tract ( present &gt; 84 day ) allow Serious nonhealing wound , ulcer , bone fracture History familial QTc prolongation syndrome Any follow condition = &lt; 6 month prior registration : Cerebrovascular accident ( CVA ) transient ischemic attack ( TIA ) Serious unstable cardiac arrhythmia Admission unstable angina myocardial infarction Cardiac angioplasty stenting Coronary artery bypass graft surgery Pulmonary embolism , untreated deep venous thrombosis ( DVT ) DVT treat therapeutic anticoagulation = &lt; 30 day Arterial thrombosis Symptomatic peripheral vascular disease Other active malignancy = &lt; 2 year prior registration ; EXCEPTIONS : nonmelanotic skin cancer carcinomainsitu cervix ; NOTE : history prior malignancy , must receive specific treatment cancer ; NOTE : adjuvant antiestrogen/hormonal therapy breast cancer allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>